Abstract: Provided are compositions and methods for treatment of cancer and for adoptive T cell therapy (ACT). The compositions comprise one or more derivatives of tricin 7-O-?-D-glucopyranoside (ANTARTINA®). The compositions comprise one or more pharmaceutically acceptable excipients convenient for delivery of the tricin 7-O-?-D-glucopyranoside derivatives. Tricin 7-O-?-D-glucopyranoside derivatives described herein include acetylated tricin 7-O-?-D-glucopyranoside, as well as glucose, maltose, cellobiose, lactose, xylose, and galactose derivatives. The methods include treatment, or reduction in the risk of suffering from, colorectal cancer and hepatocellular cancer.

Abstract: Provided are compositions and methods for treatment of cancer and for adoptive T cell therapy (ACT). The compositions comprise one or more derivatives of tricin 7-O-?-D-glucopyranoside (ANTARTINA®). The compositions comprise one or more pharmaceutically acceptable excipients convenient for delivery of the tricin 7-O-?-D-glucopyranoside derivatives. Tricin 7-O-?-D-glucopyranoside derivatives described herein include acetylated tricin 7-O-?-D-glucopyranoside, as well as glucose, maltose, cellobiose, lactose, xylose, and galactose derivatives. The methods include treatment, or reduction in the risk of suffering from, colorectal cancer and hepatocellular cancer.

Abstract: Novel pyroglutamic acid derivatives (I), wherein R1 is —OH, —ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing group; either in the form of their isolated optically active stereoisomers or in the form of mixtures thereof, are useful compounds for enhancing an immuneresponse in a subject and/or for treating tumors, bacterial, fungal or viral infections, or autoimmune diseases.

Abstract: Novel pyroglutamic acid derivatives (I), wherein R1 is —OH, —ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing group; either in the form of their isolated optically active stereoisomers or in the form of mixtures thereof, are useful compounds for enhancing an immuneresponse in a subject and/or for treating tumors, bacterial, fungal or viral infections, or autoimmune diseases.

Abstract: Novel pyroglutamic acid derivatives (I), wherein R1 is —OH, —ORa, wherein Ra is alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or heterocyclyl; R2, R3 and R4 are independently H, a nitrogen protecting group which hydrolyzes under acidic conditions or phtalamide; X is a pharmaceutically acceptable anion; and Y is a N-containing group; either in the form of their isolated optically active stereoisomers or in the form of mixtures thereof, are useful compounds for enhancing an immuneresponse in a subject and/or for treating tumours, bacterial, fungal or viral infections, or autoimmune diseases.

Abstract: The present invention is a chemical composition including: Use of the compound with the chemical formula can be applied in pharmaceutical compositions for the treatment of psoriasis.